TY - JOUR
T1 - Head‐to‐head comparison of CLSI, EUCAST, Etest and VITEK®2 results for Candida auris susceptibility testing
AU - Ceballos-Garzon, Andrés
AU - Garcia-Effron, Guillermo
AU - Cordoba, Susana
AU - Rodriguez, Jose Y.
AU - Alvarez-Moreno, Carlos
AU - Pape, Patrice Le
AU - Parra-Giraldo, Claudia Marcela
AU - Morales-López, Soraya
N1 - Publisher Copyright:
© 2022 Elsevier Ltd and International Society of Antimicrobial Chemotherapy
PY - 2022/4
Y1 - 2022/4
N2 - The susceptibility of 31 Candida auris clinical isolates was evaluated by four methods, namely the microdilution reference method according to Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines as well as Etest and VITEK®2. Essential agreement between the two reference methods was 90%. Etest showed a better overall agreement with the reference methods (94% and 81% for CLSI and EUCAST, respectively) than VITEK®2 (70% and 72%, respectively). Discrepancies were found for fluconazole (FLC) and amphotericin B. Considering categorical agreement (CDC tentative breakpoints), the majority of isolates were considered FLC-resistant (93.6% and 80.6% by CLSI and EUCAST, respectively). Furthermore, all isolates were considered susceptible to echinocandins by all methods. Susceptibility results should be interpreted with care if the VITEK®2 system is used to guide therapeutic decisions for C. auris infections.
AB - The susceptibility of 31 Candida auris clinical isolates was evaluated by four methods, namely the microdilution reference method according to Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines as well as Etest and VITEK®2. Essential agreement between the two reference methods was 90%. Etest showed a better overall agreement with the reference methods (94% and 81% for CLSI and EUCAST, respectively) than VITEK®2 (70% and 72%, respectively). Discrepancies were found for fluconazole (FLC) and amphotericin B. Considering categorical agreement (CDC tentative breakpoints), the majority of isolates were considered FLC-resistant (93.6% and 80.6% by CLSI and EUCAST, respectively). Furthermore, all isolates were considered susceptible to echinocandins by all methods. Susceptibility results should be interpreted with care if the VITEK®2 system is used to guide therapeutic decisions for C. auris infections.
KW - CLSI
KW - Candida auris
KW - EUCAST
KW - Etest
KW - Susceptibility testing
UR - http://www.scopus.com/inward/record.url?scp=85127325120&partnerID=8YFLogxK
U2 - 10.1016/j.ijantimicag.2022.106558
DO - 10.1016/j.ijantimicag.2022.106558
M3 - Article
C2 - 35227828
AN - SCOPUS:85127325120
SN - 0924-8579
VL - 59
JO - International Journal of Antimicrobial Agents
JF - International Journal of Antimicrobial Agents
IS - 4
M1 - 106558
ER -
